Neoadjuvant chemotherapy followed by surgery has no therapeutic advantages over concurrent chemoradiotherapy in International Federation of Gynecology and Obstetrics stage IB-IIB cervical cancer.
Jeongshim LeeTae Hyung KimGwi Eon KimKi Chang KeumYong Bae KimPublished in: Journal of gynecologic oncology (2016)
NACT+S has no therapeutic advantages over CCRT, the standard treatment. Therefore, NACT+S should be considered only in selected patients through multidisciplinary discussion or clinical trial setting.
Keyphrases
- neoadjuvant chemotherapy
- locally advanced
- clinical trial
- rectal cancer
- end stage renal disease
- ejection fraction
- chronic kidney disease
- lymph node
- newly diagnosed
- minimally invasive
- sentinel lymph node
- coronary artery bypass
- prognostic factors
- acute coronary syndrome
- coronary artery disease
- study protocol
- patient reported outcomes
- atrial fibrillation
- open label
- phase ii
- double blind
- patient reported